FMR LLC - MOONLAKE IMMUNOTHERAPEUTICS ownership

MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 122 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q3 2023. The put-call ratio across all filers is 13.14 and the average weighting 1.0%.

Quarter-by-quarter ownership
FMR LLC ownership history of MOONLAKE IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2023$193,643,420
+12.4%
3,397,253
+0.6%
0.02%
+21.4%
Q2 2023$172,264,995
+747.0%
3,377,745
+255.2%
0.01%
+1300.0%
Q1 2023$20,338,980
+944.2%
950,864
+412.6%
0.00%
Q4 2022$1,947,750
-70.1%
185,500
-77.4%
0.00%
-100.0%
Q3 2022$6,521,000
+4.1%
819,177
-31.4%
0.00%0.0%
Q2 2022$6,264,0001,193,2900.00%
Other shareholders
MOONLAKE IMMUNOTHERAPEUTICS shareholders Q3 2023
NameSharesValueWeighting ↓
BVF INC/IL 21,751,284$1,239,823,18833.43%
Cormorant Asset Management, LP 8,142,100$464,099,70027.07%
Ally Bridge Group (NY) LLC 183,105$10,436,98512.25%
Finepoint Capital LP 331,416$18,890,7129.41%
Ghost Tree Capital, LLC 330,000$18,810,0006.19%
5AM Venture Management, LLC 313,210$17,852,9705.14%
Ghost Tree Capital, LLC 250,000$14,250,0004.69%
MPM BioImpact LLC 294,190$16,768,8304.48%
Integral Health Asset Management, LLC 500,000$28,500,0003.95%
Altium Capital Management LP 88,000$5,016,0002.62%
View complete list of MOONLAKE IMMUNOTHERAPEUTICS shareholders